The most studied predictive biomarkers for response to checkpoint inhibitors include tumor mutational load, PD-1 expression, CD4/CD8 lymphocyte ratio, the percentage of tumor-infiltrating lymphocytes, and several methods of establishing immune scores [1,2,3]. The gene discussed is CD8A; the disease is neoplasm.